Breast cancer (BC) is the second most common cause of brain metastases (BM) with the highest risk (up to 50%) in patients with human epidermal growth factor receptor 2 (HER2) positive disease. For patients with breast cancer brain metastases (BCBM), the prognosis is poor and long-term survival is rare. Recently, clinical trials of targeted systemic therapies have finally begun to include patients with HER2-positive BCBM; however, the translation into clinical strategy may remain unclear as data continually evolves. For this program, 32 renowned BC specialists from the United States and the European Union completed a questionnaire documenting their perspectives on several of the field s most deeply debated and evolving issues, including optimal screening practices, monitoring techniques, and therapeutic approaches. Watch Drs Komal Jhaveri, Javier Cortes, and Sara Hurvitz discuss the results in the context of their own experiences and modern data, providing insight into evolving best practices. See how your approaches compare via intra-activity polling and gather clinical pearls to help optimize clinical decisions and improve patient outcomes.
- Provider:Partners for Advancing Clinical Education (PACE)
- Activity Link: https://nexusmedx.motivelms.com/browse/preview/324
- Start Date: 2024-12-30 06:00:00
- End Date: 2024-12-30 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 119000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 120000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all